Infographic: Rayaldee®: For Early and Sustained SHPT Control - European Medical Journal

Infographic: Rayaldee®: For Early and Sustained SHPT Control

Download PDF

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Secondary hyperparathyroidism (SHPT) is a common and early complication of chronic kidney disease (CKD). Patients with uncontrolled SHPT have high parathyroid hormone (PTH) levels due to mineral metabolism disturbances of several biochemical parameters. These elevated PTH levels put patients at an increased risk of cardiovascular disease and bone fractures. This infographic explores the current treatments available to treat mineral bone disease in CKD (CKD-MBD) and their failure to achieve balance across key disease parameters.

The publication of this infographic was funded by CSL Vifor.

This page is intended for healthcare professionals in Germany and Switzerland only.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now